Performance Analysis of Panel Reactive Antibody Test by Lambda Antigen Tray Kit using Enzyme-Linked Immunosorbent Assay.
- Author:
Sean Mi SONG
1
;
Byoung Teak PAK
;
Yun Sun YANG
Author Information
1. Department of Clinical Pathology, University of Sungkyunkwan College of Medicine Samsung Medical Center, Seoul, Korea. ssmmontblanc@hanmail.net
- Publication Type:Original Article
- Keywords:
PRA by ELISA;
CDC;
LAT kits;
HLA frequency
- MeSH:
Antibodies;
Antibody Specificity;
Centers for Disease Control and Prevention (U.S.);
Complement System Proteins;
Enzyme-Linked Immunosorbent Assay*;
Humans;
Isoantibodies;
Korea;
Leukocytes;
Mass Screening
- From:Korean Journal of Clinical Pathology
2000;20(6):583-587
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: To detect human leukocyte antigen(HLA) alloantibodies, panel reactive antibody(PRA) test using complement dependent lymphocytotoxicity(CDC) has been generally used in Korea but this method lacks standardization. We analyzed the performance of Lambda Antigen Tray(LAT, One Lambda, Inc., Canoga Park, USA) kit using Enzyme-linked immunosorbent assay(ELISA). METHODS: We carried out PRA screening by ELISA with LAT10X5 kit and CDC with home-made panels for 81 sera patients. We carried out PRA identification by ELISA with LAT1240 kit for some sera with positive or discordant results of both CDC and PRA screening by ELISA. RESULTS: The agreement of CDC and PRA screening by ELISA was 85%(69/81). In 12 sera with positive results of both CDC and PRA screening by ELISA, no sera had same results of HLA antibody specificities. HLA class II antibodies were found in 13 sera(16%) and 12 sera of those had HLA class I antibodies, too. CONCLUSIONS: The agreement of CDC and PRA screening by ELISA was similar to other foreign result. Disagreement of both methods might be due to greatly difference of frequencies of HLA in used panels. New manufactured goods considered frequencies of Korean HLA should be made in order that PRA by ELISA can be applied to routine work.
